Previous 10 | Next 10 |
Rogers Corp. (NYSE:ROG) fell 3% on a report that the China antitrust approval of Dupont's (NYSE:DD) $5.2 billion acquisition may take a little longer than expected. Dupont gained 2.7%. The transaction is said to be seeing some concerns by third parties in China, according to a ...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
Rogers press release (NYSE:ROG): Q1 Non-GAAP EPS of $1.53. Revenue of $248.3M (+8.3% Y/Y). For further details see: Rogers Non-GAAP EPS of $1.53, revenue of $248.3M
Rogers Corporation (NYSE:ROG) today announced financial results for the first quarter of 2022. “Rogers delivered solid first quarter revenue growth driven by EV/HEV, ADAS and industrial market sales,” stated Bruce D. Hoechner, Rogers' President and CEO. “Underly...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
Dupont's (NYSE:DD) planned $5.2 billion acquisition of Rogers Corp. (NYSE:ROG) is said to be approved by Korea's antitrust regulator and is seeing a smooth review in China. The Korean Fair Trade Commission cleared the transaction unconditionally earlier this month, according to a Dealreporter...
Oncolytics Biotech (NASDAQ:ONCY) is trading ~11% higher premarket after it said no safety concerns were noted in the three-patient colorectal cancer group in phase 1/2 trial testing its drug, pelareorep in combination with Roche's (ROG) atezolizumab. The company said an in...
Rogers press release (NYSE:ROG): Q4 GAAP EPS of $1.22. Revenue of $230.5M. For further details see: Rogers GAAP EPS of $1.22, revenue of $230.5M
Rogers Corporation (NYSE:ROG) today announced financial results for the full year and fourth quarter of 2021. “Rogers delivered record full-year revenue and earnings in 2021 led by tremendous growth in EV/HEV market sales,” stated Bruce D. Hoechner, Rogers' President a...
News, Short Squeeze, Breakout and More Instantly...
Stronger Gross Margin Drives Improved Results Rogers Corporation (NYSE:ROG) today announced financial results for the second quarter of 2024. "Solid execution contributed to results that were in line with our second quarter expectations,” stated Colin Gouveia, Rogers' Presi...
Roche showcases solutions for laboratories of the future at the Association for Diagnostics & Laboratory Medicine 2024 Clinical Lab Expo Roche showcases solutions for laboratories of the future at the Association for Diagnostics & Laboratory Medicine 2024 Clinical Lab Expo P...
Rogers Corporation (NYSE:ROG) (“Rogers”) plans to announce second quarter 2024 results on July 25, 2024 after market close, which will be followed by a conference call at 5:00 pm ET. The call will be hosted by Colin Gouveia, President and Chief Executive Officer, who will be joine...